The increasing longevity of patients with transfusion-dependent homozygous beta-thalassemia has brought endocrine complications to the forefront of long-term care.
While iron overload remains a central mechanism, additional contributors such as hypothalamic dysfunction, neurosecretory disturbances, and chronic inflammation have been identified.
Endocrine disorders including hypothyroidism, adrenal insufficiency, hypogonadotropic hypogonadism, hypoparathyroidism, osteoporosis, and growth axis impairment - are prevalent and often underdiagnosed.
Diagnostic challenges include normal hormone levels in early stages, necessitating the use of dynamic endocrine testing and pituitary magnetic resonance imaging to detect subclinical dysfunction.
Risk is modulated by sex, age, and chelation adherence.
Early identification and proactive, multidisciplinary management of endocrine sequelae are essential in reducing morbidity and maintaining functional independence in this aging patient population.
Core Tip:Endocrine dysfunction is a major source of long-term morbidity in transfusion-dependent beta-thalassemia.
Subtle hypothalamic-pituitary axis abnormalities, such as neurosecretory growth hormone dysfunction and tertiary adrenal insufficiency, may precede overt clinical signs.
Pituitary magnetic resonance imaging and dynamic hormone testing improve early detection.
Integrating routine endocrine screening into thalassemia care enables timely interventions that can prevent irreversible complications and enhance quality of life.
We read with great interest the recent article by Dordevicet al[1], offering a valuable overview of the pathophysiology, diagnosis and the evolving therapeutic approaches in beta-thalassemia syndromes.
As life expectancy improves, previously underrecognized complications - particularly of endocrine origin - are emerging as key determinants of long-term morbidity.
Thus, following on the article by Dordevicet al[1], we would like to enrich this perspective by presenting an update on the spectrum of endocrine dysfunction in homozygous beta-thalassemia (hBT).
Thyroid dysfunction is one of the earliest recognized endocrine abnormalities in hBT.
Both primary and central hypothyroidism are commonly reported, with an overall prevalence ranging from 15%-30% depending on age, transfusion burden, and adherence to chelation[2,3].
Iron-induced destruction of the thyroid gland can result in primary hypothyroidism, while hemosiderosis of the hypothalamic-pituitary axis contributes to central hypothyroidism.
Notably, even in the absence of overt biochemical hypothyroidism, patients with serum ferritin > 2500 ng/mL often show subclinical abnormalities such as low-normal T4 and inappropriately low thyroid stimulating hormone, underscoring the need for sensitive screening protocols[3,4].
Although historically considered rare, adrenal insufficiency (AI) has been increasingly documented among patients with hBT.
A recent meta-analysis demonstrated a pooled prevalence of 25.6%, with adult patients exceeding 51% positivity rates, particularly when using tetracosactrin stimulation[5].
Interestingly, testing methods significantly impact prevalence detection - glucagon stimulation and low-dose adrenocorticotropic hormone tests are more sensitive compared to single serum cortisol measurements.
Huanget al[6] also reported that 92% of AI cases occurred in males, possibly due to differential hypothalamic sensitivity.
Magnetic resonance imaging (MRI) data often show iron accumulation in the pituitary, yet patients exhibit normal adrenocorticotropic hormone responses to corticotropin-releasing hormone, suggesting hypothalamic dysfunction (tertiary AI) as a key pathogenic mechanism[6].
The implications are clinically relevant - undiagnosed AI may precipitate an adrenal crisis during surgery or infection.
As such, annual dynamic testing should be strongly considered in adult patients or those with unexplained fatigue, hypotension, or poor stress tolerance.
Hypogonadotropic hypogonadism is the most prevalent endocrine complication in hBT, affecting up to 80% of adults and a significant proportion of adolescents[7,8].
Its pathophysiology includes iron deposition in the anterior pituitary, leading to reduced secretion of gonadotropins.
Noetzliet al[9] demonstrated a strong inverse correlation between pituitary R2Ã—MRI values and volume with gonadotropin output, indicating early morphological and functional compromise.
Clinically, patients present with delayed or arrested puberty, amenorrhea, infertility, or low libido.
Notably, males appear to experience a more severe phenotype, with lower body mass indexz-scores and bone density, suggesting a protective effect of estrogen in females[6].
Hormone replacement therapy, though effective, must be carefully individualized, especially in the presence of comorbidities such as cardiac iron overload or liver dysfunction.
Hypoparathyroidism is a rarer yet clinically significant complication in hBT, with reported prevalence between 4%-6%[10].
It results from iron toxicity to the parathyroid glands, while its clinical manifestations may be exacerbated by coexisting vitamin D deficiency and renal tubular dysfunction, both of which are not uncommon in transfusion-dependent patients.
Hypocalcemia, tetany, perioral numbness, and seizures may occur.
De Sanctiset al[10] noted that despite improved chelation, many adult patients still demonstrate latent hypocalcemia with low PTH levels, warranting lifelong surveillance.
Correction of calcium-phosphate balance, adequate vitamin D repletion, and parathyroid hormone analogs are important management steps.
Bone complications remain a major cause of morbidity.
More than 50% of hBT patients exhibit osteopenia or osteoporosis on dual-energy X-ray absorptiometry scan, driven by a multifactorial pathogenesis[11,12].
In addition to hypogonadism, chronic anemia causes marrow expansion and cortical thinning, while iron impairs osteoblast function.
Notably, poor adherence to chelation therapy, reported in up to 43% of patients, has been strongly associated with more severe bone loss[13].
Sex differences are also notable - males exhibit more frequent and severe bone disease, potentially due to lower cumulative estrogen exposure.
Clinical care should involve early screening, nutritional support, bisphosphonates in severe cases, and treatment of coexisting endocrine dysfunctions contributing to bone fragility.
Although not extensively studied, growth hormone (GH) deficiency and other anterior pituitary hormone deficits may occur in patients with transfusion-dependent thalassemia.
Iron overload can affect the hypothalamus early, preceding overt pituitary dysfunction.
GH axis impairment may manifest as persistently low serum insulin-like growth factor-1 (IGF-1) despite normal GH responses to stimulation tests - a pattern indicative of neurosecretory dysfunction, characterized by impaired spontaneous GH pulsatility despite preserved secretory reserve[14,15].
In such cases, 24-hour GH profiling or IGF-1 generation tests may reveal subclinical hypothalamic dysfunction[15,16].
Moreover, GH insensitivity, potentially related to chronic inflammation or hepatic siderosis, may further compromise IGF-1 synthesis[14].
These observations support a more comprehensive assessment of the somatotropic axis beyond conventional GH testing.
Reduced growth velocity has been reported in pediatric patients with transfusion-dependent hBT, even in the presence of adequate transfusion and nutritional status, likely reflecting functional impairment of the somatotropic axis[14].
The potential role of MRI in early detection of hypothalamic-pituitary axis compromise should be further explored, as it may precede clinical hormone deficiencies[17-19].
The long-term endocrine sequelae in hBT are strongly influenced by therapeutic adherence, particularly to iron chelation.
Table1summarizes the prevalence, pathophysiology, clinical features, diagnostics, and management considerations across endocrine axes affected in hBT.
Lockeet al[13] demonstrated adherence variability ranging from 57% to 98%, with non-adherence contributing to worse cardiac, hepatic, and endocrine outcomes[13].
Transitioning care from pediatric to adult clinics often results in fragmentation.
We strongly support multidisciplinary teams including endocrinologists, hematologists, and reproductive specialists, with annual structured assessments covering thyroid, adrenal, gonadal, bone, and calcium metabolism.
Moreover, early MRI screening of the pituitary and routine dynamic hormonal testing may allow pre-symptomatic intervention.
AI: Adrenal insufficiency; TSH: Thyroid stimulating hormone; ACTH: Adrenocorticotropic hormone; LH: Luteinizing hormone; FSH: Follicular stimulating hormone; MRI: Magnetic resonance imaging; HRT: Hormone replacement therapy; PTH: Parathormone; DXA: Dual-energy X-ray absorptiometry; IGF-1: Insulin-like growth factor-1; GH: Growth hormone.
In conclusion, as survival in hBT improves, comprehensive endocrine care becomes indispensable.
The article by Dordevicet al[1] offers a timely opportunity to re-emphasize the importance of structured screening and management of endocrine complications.
Recognition of early subclinical dysfunction, adoption of dynamic testing protocols, and reinforcement of chelation adherence will help preserve quality of life in this unique population.